Online inquiry

IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11554MR)

This product GTTS-WQ11554MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11554MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5061MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ7093MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ1223MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ11007MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ11805MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ10149MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ4329MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW